IBERICA USA Inc. (President and CEO: Dr. Toru Mimura, “IBERICA USA”) announced today the December 14, 2007, opening of Iberica Clinical Research Center (ICRC)—a facility designed to provide more precise clinical study data through greater respect of and care for study participants. IBERICA USA and its Japanese parent company Iberica Holdings Co., Ltd. (President and CEO: Ms Misayo Abe, “Iberica Holdings”) believe that by focusing on mutual dignity and respect for all stakeholders in a clinical study, they are introducing a significant change to the phase I study environment in the US. This unique commitment to ensuring the highest levels of dignity and respect is particularly important when studying a socially devastating condition such as Alzheimer’s Disease (AD). Also the presence of Medical Director, Dr. Joel Ross—one of the foremost doctors conducting AD clinical research in the US today—will allow Sponsors to take full advantage of the facility’s design to meet the needs of early stage clinical studies not only in AD but also in a variety of other therapeutic areas.

ICRC has 20 single rooms and 4 twin rooms, 28 beds in total, all with private bathroom and toilet facilities and is designed to provide unprecedented comfort and relaxation to study participants. The center’s twin rooms allow caregivers to stay overnight with participants, making it ideal for studies both in studies involving patients with AD and in pediatriac studies, where the presence of a loved one provides the participant with a greater peace of mind. The design of ICRC helps minimize stress on these vulnerable patient populations, helping to eliminate this potentially confounding variable in clinical studies while optimizing patient care. With qualified Japanese nurses and translators available 24 hours a day, ICRC will be able to efficiently conduct scientifically rigorous studies to evaluate differences in pharmacokinetics and pharmacodynamics between Japanese and non-Japanese populations. In addition to these types of studies, ICRC remains perfect for conducting standard early stage clinical research and will provide a greater level of trust in the validity of clinical data.